Rebel Medicine Inc has closed a $6 million Series A financing led by Crocker Ventures to advance its non-opioid pain therapeutic Alevatrix™ into clinical development.
Jun 12, 2025•2 months ago
Amount Raised
$6 Million
Round Type
series a
Salt Lake CityHealth CareInvestors
Cantina AngelsThe Joan & Tim Fenton FundSk HartUtah Innovation FundProsperity Solutions CapitalCentral Texas Angel Network (Ctan)Crocker Ventures
Description
Rebel Medicine Inc, a clinical-stage biotechnology company, announced the closing of its $6 million Series A financing. Led by Crocker Ventures, the financing will help advance Alevatrix™, their non-opioid pain drug candidate, into clinical trials. The funding coincides with their IND application opening with the FDA. This successful fundraise validates their vision and accelerates the clinical development of their technologies.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers